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Background
It is unclear what constitutes a clinically-meaningful
response for allergic rhinitis (AR) outcomes. In a recent
survey [1] most experts defined control as being “hardly
troubled at all” by each symptom. We propose a new
criterion of ≤1 point remaining in each nasal symptom
score (Max AM+PM score for each symptom=6) of the
reflective total nasal symptom score (rTNSS) to strin-
gently test efficacy and provide an endpoint meaningful
to physicians and patients. This criterion has been
termed complete/near-to-complete symptom control.
Any treatment providing this level of control (patients
will feel “cured”) should have considerable socioeco-
nomic impact.
Objective
To compare the proportion of patients achieving ≤1 point
remaining in each of the 4 symptoms of the rTNSS (con-
gestion, itching, rhinorrhoea & sneezing) and the time
taken to achieve this response in patients treated with
MP29-02* (a novel intranasal formulation of azelastine
hydrochloride [AZE] and fluticasone propionate [FP]), FP,
AZE or placebo (PLA) nasal sprays.
Methods
610 patients (≥12 years old) with moderate-to-severe sea-
sonal AR were randomized into a double-blind, placebo-
controlled, 14 day parallel-group trial to receive MP29-
02*, commercially-available AZE or FP nasal sprays or
PLA nasal spray (all 1 spray/nostril bid; total daily dose
[AZE: 548µg, FP: 200µg]). The primary outcome was
change from baseline in rTNSS over 14-days. Time to
achieve ≤1 point remaining in each nasal symptom (AM +
PM) of the rTNSS was assessed post-hoc by Kaplan-Meier
estimates and log rank tests.
Results
17.8% of MP29-02* patients (1 out of 6) achieved this
response versus 8.3%, 9.2% and 7.8% of those treated with
AZE, FP and PLA, respectively. MP29-02* patients
achieved this response up to 7 days faster than AZE
(p=0.0152) and up to 8 days faster than either FP
(p=0.0262) or PLA (p=0.0094). Neither AZE nor FP dif-
fered from PLA for this parameter.
Conclusion
MP29-02* provides faster and more complete symptom
control than first-line therapies for AR. One out of 6 mod-
erate to severe AR patients achieved complete/near-to-
complete and uniform symptom relief days faster than
either FP or AZE. MP29-02* is the drug of choice for AR
treatment since it was the only therapy to rapidly provide
such a level of symptom control. This endpoint should
become a new standard in assessing the efficacy of current
and novel AR therapy.
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